Artelo Biosciences Files 8-K with Corporate Updates
Ticker: ARTL · Form: 8-K · Filed: Nov 14, 2025 · CIK: 1621221
Sentiment: neutral
Topics: corporate-governance, filing-update, exhibits
Related Tickers: ARTL
TL;DR
ARTL files 8-K: Corporate docs updated, financials included. Keep an eye on changes.
AI Summary
Artelo Biosciences, Inc. filed an 8-K on November 14, 2025, reporting on events that occurred on November 10, 2025. The filing indicates amendments to its Articles of Incorporation or Bylaws and includes financial statements and exhibits. The company, previously known as Reactive Medical Inc. and Knight Knox Development Corp., is incorporated in Nevada and has its principal executive offices in Solana Beach, California.
Why It Matters
This 8-K filing signals potential changes in Artelo Biosciences' corporate structure or governance, which could impact its operational direction and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting corporate changes and exhibits, not indicating immediate financial distress or significant operational shifts.
Key Players & Entities
- ARTELO BIOSCIENCES, INC. (company) — Registrant
- November 10, 2025 (date) — Earliest event reported
- November 14, 2025 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
- Solana Beach, CA (location) — Principal executive offices
- REACTIVE MEDICAL INC. (company) — Former company name
- KNIGHT KNOX DEVELOPMENT CORP. (company) — Former company name
FAQ
What specific amendments were made to the Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information of the 8-K.
What are the key financial statements included in this filing?
The filing states that financial statements and exhibits are included, but the specific content of these financial statements is not detailed in the provided text.
When was Artelo Biosciences, Inc. previously known as Reactive Medical Inc. and Knight Knox Development Corp.?
The company's name was changed from Reactive Medical Inc. on February 7, 2017, and from Knight Knox Development Corp. on October 1, 2014.
What is the primary business of Artelo Biosciences, Inc. according to its SIC code?
Artelo Biosciences, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Artelo Biosciences, Inc.?
The fiscal year end for Artelo Biosciences, Inc. is December 31.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-11-14 16:07:43
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ARTL The Nasdaq Stock Mar
Filing Documents
- artl_8k.htm (8-K) — 25KB
- artl_ex31.htm (EX-3.1) — 3KB
- 0001640334-25-002118.txt ( ) — 148KB
- artl-20251110.xsd (EX-101.SCH) — 5KB
- artl-20251110_lab.xml (EX-101.LAB) — 15KB
- artl-20251110_cal.xml (EX-101.CAL) — 1KB
- artl-20251110_pre.xml (EX-101.PRE) — 10KB
- artl-20251110_def.xml (EX-101.DEF) — 2KB
- artl_8k_htm.xml (XML) — 4KB
03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 10, 2025, the board of directors (the "Board") of Artelo Biosciences, Inc. (the "Company") amended the Company's amended and restated bylaws (the "Bylaws"), as provided in a Certificate of Amendment to Bylaws (the "Bylaws Amendment"), as follows: The Bylaws have been updated to provide that the right of stockholders to fill vacancies in the Board has been eliminated; and The Bylaws have been updated to provide that directors shall be elected at a meeting of the stockholders by a plurality of the votes cast at the election. The Bylaws Amendment is filed as Exhibit 3.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Exhibit 3.1 Certificate of Amendment to Bylaws 104 Cover Page Interactive Data File (embedded within the XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARTELO BIOSCIENCES, INC. Date: November 14, 2025 /s/ Gregory D. Gorgas Gregory D. Gorgas President & Chief Executive Officer 3